Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adnexus, Bristol-Myers deal

BMY will acquire Adnexus for $430 million in cash, plus up to $75 million

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE